Diabetes develops when the body loses functional β cells or when those cells can no longer release enough insulin to control blood glucose. Insulin-producing β cells occupy only a small fraction of the pancreatic islet, where they coexist with several other endocrine cell types, including α cells. α cells normally produce glucagon, a hormone that raises blood glucose when it falls too low. Because α cells are abundant, closely related to β cells and located in the same tissue environment, scientists have explored whether they could be redirected to replace lost β cells.

Previous studies have identified chemical compounds capable of making α cells display selected β cell-like characteristics. However, converting a cell’s identity is more complicated than switching on a handful of genes. A successful conversion must also establish the metabolic machinery required for the new function. β cells are specialized not only to produce insulin but also to sense glucose, process nutrients and release insulin in a precisely regulated manner. The new study addresses this deeper layer of cellular identity by linking gene regulation to metabolism.

The researchers identified inhibitors of polycomb repressive complex 2, or PRC2, as strong inducers of β cell-enriched gene expression in α cells. PRC2 is an epigenetic regulatory complex: it modifies chromatin, the DNA-protein structure that determines which genes are accessible for transcription. By placing repressive chemical marks on histone proteins, PRC2 can silence groups of genes involved in cell identity and development. Blocking PRC2 appears to relax this repression, allowing α cells to activate genes more commonly associated with β cells.

The study connects this process to a molecular partnership involving the androgen receptor, known as AR, and the transcription factor ETV1. Transcription factors act as molecular switches that bind DNA and coordinate gene activity, while nuclear receptors such as AR can alter transcription in response to regulatory signals. According to the researchers, PRC2 inhibition changes the activity of the AR–ETV1 complex, helping α cells move toward a β cell-like gene-expression state. This finding suggests that cellular reprogramming is controlled by a network rather than a single master switch.

The most striking result came when the team examined metabolism. α cells exposed to AR inhibition showed reduced glycogen synthesis and increased activity in the pentose phosphate pathway, or PPP. This pathway branches from glucose metabolism and generates NADPH, a reducing molecule that helps protect cells from oxidative stress, as well as ribose-5-phosphate, a building block required for nucleotide production. By redirecting glucose-derived carbon into the PPP, cells can alter their redox balance, biosynthetic capacity and signaling environment—changes that may help support a new cellular identity.

To test whether this metabolic shift could be induced directly, the researchers used methyl esterified 6-phosphogluconate. The compound is a chemically modified form of 6-phosphogluconate, an intermediate in the pentose phosphate pathway. Methyl esterification can improve a molecule’s ability to cross cell membranes, allowing researchers to deliver the metabolite into cells more efficiently. The treatment induced β cell-like features in α cells, indicating that metabolism was not merely a passive consequence of reprogramming but could act as an active driver of the process.

The researchers further report that this metabolic intervention stimulated β cell regeneration and improved diabetes-related outcomes in experimental systems. These findings are important because they point beyond pharmacologically manipulating gene expression alone. Instead, they suggest that changing the flow of nutrients through a cell can help unlock latent developmental programs. In this model, the metabolic state of an α cell appears to influence which genes it can activate and whether it can acquire functions associated with insulin-producing β cells.

The work also highlights the challenges that remain before such an approach could be considered for human therapy. A cell that expresses some β cell markers may not yet be a fully functional β cell, and researchers must establish whether converted cells release insulin appropriately, respond safely to changing glucose levels and remain stable over time. The effects of PRC2, AR and ETV1 are likely to vary across tissues, raising questions about unwanted gene activation or side effects. Nonetheless, the study presents a compelling framework: restoring β cell mass may be possible not only by transplanting cells or forcing genetic changes, but also by rewiring the metabolic circuitry of cells already present in the pancreas. Further work will be needed to determine whether this strategy can be translated safely from experimental models into a treatment for people with diabetes.

Subject of Research: Metabolic reprogramming of pancreatic α cells into insulin-producing β-like cells and β cell regeneration.

Article Title: Metabolic reprogramming drives pancreatic β cell neogenesis from α cells

Article References: Zhang, Y., Lu, G., Xie, W. et al. Metabolic reprogramming drives pancreatic β cell neogenesis from α cells. Nature Chemical Biology (2026). https://doi.org/10.1038/s41589-026-02293-z

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41589-026-02293-z

Keywords: diabetes, pancreatic β cells, α cells, metabolic reprogramming, pentose phosphate pathway, PRC2 inhibitors, androgen receptor, ETV1, insulin, β cell regeneration

In a groundbreaking development, researchers from the University of Missouri School of Medicine have pioneered an innovative approach to islet transplantation that circumvents the necessity for chronic immunosuppressive regimens. This novel strategy hinges on the precise bioengineering of donor islets through the covalent attachment of two immune-modulatory molecules: thrombomodulin and CD47. Thrombomodulin, an endothelial cell surface glycoprotein, is known for its anti-inflammatory and anticoagulant properties. It inhibits the activation of the complement cascade and attenuates detrimental inflammatory responses that typically lead to early islet destruction post-transplant. Concurrently, CD47 serves as a “don’t eat me” signal by engaging signal regulatory protein alpha (SIRPα) receptors on macrophages and other immune effector cells, effectively signaling these cells to inhibit phagocytosis and cytotoxic attacks against the graft.

The synergy of thrombomodulin and CD47 integration onto islet surfaces has demonstrated remarkable efficacy in preclinical animal models. The researchers reported that over 72% of recipients transplanted with these co-engineered islets exhibited normalization of blood glucose levels without exogenous insulin administration—a critical milestone indicating functional restoration of endogenous insulin secretion in response to physiological glucose stimuli. This metabolic restoration attests to the bioengineered islets’ ability to maintain glucose sensing and insulin secretory functions, highlighting their clinical potential to transcend the limitations of current insulin therapy regimes.

Significantly, this bioengineering approach offers targeted immune evasion, reducing systemic exposure to immunosuppressive drugs and thereby mitigating associated risks such as nephrotoxicity, hepatotoxicity, and compromised host immunity. By localizing immune modulation to the transplant microenvironment, the transplanted islets evade innate and adaptive immune responses, extending graft survival and functional longevity. The technique exemplifies precision medicine at the cellular interface, leveraging molecular cues to harmonize transplanted tissue with the host immune milieu.

Study lead, Dr. Haval Shirwan, emphasized the transformative promise of this method: “Traditional immunosuppressants systemically weaken the host immune defense, imposing significant side effect burdens. Our approach shields the islets directly, creating a molecular armor that allows transplanted cells to blend seamlessly without evoking immune hostility.” Shirwan’s insights reflect a paradigm shift towards localized immune modulation, which could redefine the therapeutic landscape for autoimmune diseases beyond T1D.

Dr. Esma Yolcu, co-author and principal investigator in pediatric immunology, elaborated on the mechanistic basis: “Thrombomodulin attenuates deleterious inflammation by modulating coagulation and complement pathways, which are key contributors to early graft loss. CD47 operates as a critical immune checkpoint ligand, inhibiting phagocytosis by macrophages and dendritic cells. Together, they synergize to create an immunological ‘cloak’ that significantly boosts islet survival compared to the application of either molecule alone.” These findings underline the necessity of a combinatorial approach in immune engineering for transplant tolerance.

Importantly, the preclinical studies were conducted in allogeneic recipients, a model mimicking the genetic disparity between donor and recipient that typically precipitates transplant rejection. The sustained graft viability and functional insulin output observed in these models, without chronic immunosuppressant administration, forecast promising translational potential. While the experiments utilized animal subjects to establish proof-of-concept, the methodology’s translational trajectory towards human clinical trials is eagerly anticipated.

The implications of this research extend far beyond T1D management. By refining the interface between transplanted tissues and the immune system, this technology paves the way for advancements in bioengineered organ and cell therapies, fundamentally reshaping regenerative medicine. The selective modification of donor cells to skirt immune detection represents an elegant solution to one of transplantation medicine’s most intractable problems—immune rejection—without compromising systemic immune competence.

Currently, approximately 2 million individuals in the United States alone live with T1D, a population that is projected to expand as incidence rates climb globally. The burden of lifelong insulin dependence, frequent glycemic monitoring, and risk of hypoglycemic events underscore the urgent need for innovative disease-modifying therapies. This compelling research underscores the feasibility of developing transplantation-based cures that bypass the systemic toxicities of immunosuppressive drugs, promising enhanced quality of life and reduced long-term complications for patients.

Future studies will need to rigorously evaluate the safety profile and efficacy of this islet-engineering platform in human subjects. Key translational hurdles include scalable manufacturing of engineered islets, ensuring durable expression or retention of immune-regulatory molecules, and comprehensive immunological assessments within human immune systems’ complexity. However, the foundational science detailed in this study constitutes a milestone, demonstrating the concept’s viability and heralding a new dawn in the quest to cure autoimmune diabetes.

The study, titled “Islets co-engineered with thrombomodulin and CD47 achieve sustained survival in allogeneic recipients without chronic immunosuppression,” was published in JCI Insight. It represents a collaborative effort among molecular microbiologists, immunologists, and pediatric researchers who collectively leveraged cutting-edge bioengineering and immunological principles to overcome longstanding obstacles in islet transplantation.

This research exemplifies the confluence of molecular immunology, bioengineering, and clinical innovation, underscoring how understanding and manipulating immune checkpoints and inflammatory cascades at the cellular level can catalyze therapeutic breakthroughs. By harnessing nature’s own regulatory molecules, the investigators have established a promising pathway toward durable islet graft survival, potentially obviating the need for life-altering insulin therapy in T1D.

As this research progresses toward clinical validation, it also opens broader dialogues on tailoring immune evasion mechanisms for a spectrum of cell and tissue transplants, illuminating the future of precision immunotherapy in regenerative medicine. The fusion of molecular engineering and immunomodulation may very well transform autoimmune disease management and organ transplantation, with the promise of restoring physiological function with minimal adverse effects.

Subject of Research: Animals
Article Title: Islets co-engineered with thrombomodulin and CD47 achieve sustained survival in allogeneic recipients without chronic immunosuppression
News Publication Date: 17-Mar-2026
Web References: http://dx.doi.org/10.1172/jci.insight.200686
Keywords: Type 1 diabetes, Islet transplantation, Autoimmune disorders, Pancreas, Islets of Langerhans, Insulin, Immunomodulation, Thrombomodulin, CD47, Immune evasion, Regenerative medicine, Immunosuppressant alternative